Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label Study of CVM-1118 Administered Orally to Patients With Advanced Neuroendocrine Tumors

NCT03600233 is registered in ClinicalTrials.gov with TaiRx, Inc. as lead sponsor.

NCT NCT03600233
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03600233 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label Study of CVM-1118 Administered Orally to Patients With Advanced Neuroendocrine Tumors
Lead sponsor
TaiRx, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 15, 2018
Completion date
March 31, 2026
Enrollment
34 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

gastro-enteropancreatic neuroendocrine tumor, lung neuroendocrine neoplasm, neuroendocrine carcinoma, neuroendocrine tumors, pancreatic neuroendocrine tumor